1 and MWCL-1 Waldenström's macroglobulinemia cell lines and was not expressed in IgM-secreting WSU and Ramos cell lines, which carry an 8;14 translocation, nor in any myeloma cell lines.

Table 1. Summary of the Impact of MYD88 and CXCR4 Mutation Status on Treatment Outcomes in Patients With Waldenström Macroglobulinemia Fig 2. Genomic-based treatment algorithm for symptomatic, ...

Ibrutinib is an orally administered, small-molecule inhibitor of BTK that triggers apoptosis of Waldenström’s macroglobulinemia cells with MYD88 L265P. Clinical activity of ibrutinib in patient ...

In a recent study published in the Journal of Experimental Medicine, researchers identified that individuals with a deficiency of myeloid differentiation primary response 88 (MyD88) and ...

Brukinsa led to higher complete response (no evidence of cancer left) or very good partial response rates than Imbruvica (ibrutinib) for patients with Waldenström macroglobulinemia that harbored a ...

Apart from already confirmed TP53 mutations, the novel candidates: NOTCH1, SF3B1, and MYD88 might represent clinically relevant biomarkers. OBJECTIVES The aim of this study was to evaluate the ...